Regional out-licensing of
IFNa-Kinoid® for Lupus (SLE) and DM to
in Turkey
€ 6,000,000
in Greater CHINA and Singapore
€ 65,000,000
in South Korea
€ 5,000,000
Asset sale of
PDE2 research program to
Not Disclosed
Licensing and collaboration of
PDE10 program for Schizophrenia to
$ 110,000,000
R&D Collaboration of
formulation and drug discovery technologies with
IL-15 antagonist for RA and Transplantation to
$ 90,000,000
Technology out-licensing of
research tools to
Not disclosed
Out-licensing of
Yondelis (trabectedin)for soft-tissue sarcoma and ovarian cancer to
Upfront: 1 bln Yen
Kahahalide F for non-oncology indications to
KF-analogs for uses outside of oncology and neurology to
liposomal doxorubicin (Lipodox)to
In-Licensing of commercial, manufacturing, development rights
Oncophage (commercial/approved product)to
In-Licensing and co-development agreement
Quisinostat (HDAC inhibitor Phase I/II)to
